SYRE
Not exactly a standing ovation
Spyre Therapeutics got a small but meaningful tap on the shoulder this weekend: Wall Street Zen upgraded the biotech from sell to hold. Not exactly fireworks, but in analyst-land, that’s the difference between “please leave the building” and “let’s see how this goes.”
The bigger vibe check
The more interesting part is the broader chorus around SYRE. Several firms have stayed bullish or gotten even more optimistic lately, including:
- Leerink Partners lifting its target to $106
- BTIG Research raising its target to $98
- Stifel Nicolaus moving to $92
- Baird boosting its target to $90
So while Wall Street Zen only brought Spyre up to neutral territory, the overall setup still looks pretty friendly.
Why investors care
Spyre is still in the classic biotech trapdoor zone: exciting story, but no profits yet and a negative EPS outlook hanging around like an uninvited guest. That means analyst sentiment can matter a lot more than usual, because the stock is living and dying by expectations, not earnings power.
The fine print
There’s also a bit of insider selling in the background — about 62,958 shares worth roughly $2.73 million last quarter, according to the filing notes. That doesn’t automatically mean doom, but it does give investors one more thing to keep an eye on while the Street debates how much upside is left.
Big picture: this wasn’t a moonshot catalyst, but it does keep Spyre in the “still interesting” bucket instead of the “hard pass” pile.